RGRX (Regenerx Biopharmaceuticals) Beginning Cash Position: $0.29 Mil (As of Mar. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Regenerx Biopharmaceuticals Beginning Cash Position?

Regenerx Biopharmaceuticals RGRX Beginning Cash Position is $0.29 Mil as of Mar. 2023.

Regenerx Biopharmaceuticals's Beginning Cash Position for the quarter that ended in Mar. 2023 was $0.29 Mil.

Regenerx Biopharmaceuticals's quarterly Beginning Cash Position declined from Sep. 2022 ($0.71 Mil) to Dec. 2022 ($0.48 Mil) and declined from Dec. 2022 ($0.48 Mil) to Mar. 2023 ($0.29 Mil).

Regenerx Biopharmaceuticals's annual Beginning Cash Position declined from Dec. 2020 ($0.64 Mil) to Dec. 2021 ($0.43 Mil) but then increased from Dec. 2021 ($0.43 Mil) to Dec. 2022 ($1.23 Mil).

Regenerx Biopharmaceuticals Beginning Cash Position Related Terms

Regenerx Biopharmaceuticals Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Regenerx Biopharmaceuticals's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenerx Biopharmaceuticals Beginning Cash Position Chart

Regenerx Biopharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Beginning Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.18 0.24 0.64 0.43 1.23

Regenerx Biopharmaceuticals Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.23 0.93 0.71 0.48 0.29

Regenerx Biopharmaceuticals Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $0.29 Mil mean?
Regenerx Biopharmaceuticals (RGRX) has a Beginning Cash Position of $0.29 Mil as of Mar. 2023. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Regenerx Biopharmaceuticals and its competitors.
Is Regenerx Biopharmaceuticals' Beginning Cash Position too high?
Regenerx Biopharmaceuticals' current Beginning Cash Position is $0.29 Mil.
How does Regenerx Biopharmaceuticals' Beginning Cash Position compare to MYMX and RGMP?
Regenerx Biopharmaceuticals' Beginning Cash Position of $0.29 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Regenerx Biopharmaceuticals and its competitors. Regenerx Biopharmaceuticals's current Beginning Cash Position is $0.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenerx Biopharmaceuticals stock overvalued right now?
Regenerx Biopharmaceuticals (RGRX) has a current Beginning Cash Position of $0.29 Mil. The current Beginning Cash Position is $0.29 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Regenerx Biopharmaceuticals (RGRX), the current Beginning Cash Position is $0.29 Mil as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regenerx Biopharmaceuticals Business Description

Address 15245 Shady Grove Road, Suite 470, Rockville, MD, USA, 20850
Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.